Search results
IPO Stock Of The Week: AI Stock Samsara Hits Early Buy Trigger
Investor's Business Daily· 3 days agoIPO Stock Of The Week and artificial intelligence leader Samsara is decisively back above a key...
Forget Chipotle's Stock Split: Buy This Monster Restaurant Growth Stock Instead
Motley Fool via Yahoo Finance· 5 hours agoPosting a total return level of 7,000% since its initial public offering (IPO), the stock has...
3 Speculative Stocks That Could Make You a Fortune (if You Dare)
InvestorPlace· 6 days agoSpeculation is rife in the market right now and there are plenty of risky stocks for investors to...
Nio Stock: Buy, Sell, or Hold?
Motley Fool via Yahoo Finance· 6 hours agoThat acceleration indicated that Nio's business was stabilizing, but its stock still trades 16% below its initial public offering (IPO) price of $6.26...
Where Will Pinterest Stock Be in 1 Year?
Motley Fool via Yahoo Finance· 1 hour agoWhere will Pinterest's stock be in a year? Pinterest has clearly overcome its post-pandemic slowdown and continues...media market with its interest-based...
3 Top Stocks to Buy in May
Motley Fool via Yahoo Finance· 8 hours agoKeep an eye on the earnings report next week, as the stock could soar on good news. Should you invest $1,000 in Amazon right now? Before you buy
Is It Worth Betting on Rivian (RIVN) Ahead of Q1 Earnings?
Zacks via Yahoo Finance· 6 hours agoAs Rivian (RIVN) grapples with EV demand challenges and operational hurdles, consider waiting for...
Is Snap Stock a Buy Now?
Motley Fool via Yahoo Finance· 1 day agoSnap's headline numbers looked healthy, but its stock remains more than 10% below its IPO price from 2017. Is it finally the right time to buy& ...
Dow Jones Futures Rise; Palantir, AI Plays On Tap After Stock Market, Nvidia Make Bullish Moves
Investor's Business Daily· 8 hours agoIt has a new base with a 307.74 buy point. Astera Labs also reports Tuesday night, its first...
Dyne Therapeutics’ (DYN) “Buy” Rating Reaffirmed at Chardan Capital
ETF DAILY NEWS· 11 hours agoDyne Therapeutics (NASDAQ:DYN – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at Chardan Capital in a report released ...
